MarketCapExport financials
ICU Medical (ICUI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
ICU Medical Income Statement 2025-2006 | ICUI
Brief overview of profit and loss at ICU Medical
This overview is based on financial performance over the past five years. According to figures from ICU Medical, revenue changed from 1.3 billion dollars to 2.2 billion dollars over five years. Across the full period, sales moved by +75.6%; the average annual rate was 11.9%. Top-line growth remained consistently strong over the period.
Gross profit was 461 million dollars at the start and 822 million dollars at the end of the period (+78.1%). Cost of revenue moved broadly in line with sales. Comparing the endpoints gives gross margins of 36.3% and 36.8%. The gross margin stayed within a similar range.
The operating result measured by EBITDA moved from 184 million dollars to 244 million dollars, or +32.5%. The operating result developed less favorably than sales. Comparing the endpoints gives EBITDA margins of 14.5% and 10.9%. The margin contraction indicates weaker operating efficiency.
Net income changed from 86.9 million dollars to 732 thousand dollars (−99.2%). The business generated less net income by the end of the period.
The market value of the business moved from $4.3 billion to $3.7 billion, or −15.4%. The financial trend was stronger than the market valuation.
Summary assessment
Positive developments coexist with areas of weakness. The constructive conclusion rests on steady gross profitability and sales growth. The most visible risks are weaker operating efficiency and a weaker final result. Future reports should be judged by revenue momentum, margins, and the conversion of sales into net income.
Annual Income Statement ICU Medical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
3.67 B | 3.65 B | 2.56 B | 4.24 B | 5.02 B | 4.34 B | 3.83 B | 4.9 B | 4.56 B | 2.19 B | 1.53 B | 1.28 B | 952 M | 859 M | 634 M | 422 M | 544 M | 361 M | 588 M | - |
Shares |
24.6 M | 24.4 M | 24.1 M | 23.9 M | 21.2 M | 20.9 M | 20.6 M | 20.4 M | 19.6 M | 16.2 M | 15.8 M | 15.3 M | 14.7 M | 14.2 M | 13.8 M | 13.6 M | 14.7 M | 14.1 M | 14.3 M | - |
Historical Prices |
149 | 150 | 106 | 178 | 237 | 208 | 196 | 246 | 231 | 150 | 91.9 | 88.9 | 57.9 | 56.8 | 45.9 | 31 | 37 | 25.5 | 41.2 | 41.2 |
Net Income |
732 K | -118 M | -29.7 M | -74.3 M | 103 M | 86.9 M | 101 M | 28.8 M | 68.6 M | 63.1 M | 45 M | 26.3 M | 40.4 M | 41.3 M | 44.7 M | 29.9 M | 25 M | 24.3 M | 23.1 M | - |
Revenue |
2.23 B | 2.38 B | 2.26 B | 2.28 B | 1.32 B | 1.27 B | 1.27 B | 1.4 B | 1.29 B | 379 M | 342 M | 309 M | 314 M | 317 M | 302 M | 283 M | 229 M | 205 M | 188 M | - |
Cost of Revenue |
1.41 B | 1.56 B | 1.52 B | 1.58 B | 825 M | 810 M | 794 M | 830 M | 867 M | 178 M | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
822 M | 825 M | 740 M | 698 M | 491 M | 461 M | 472 M | 570 M | 426 M | 201 M | 181 M | 151 M | 155 M | 157 M | 142 M | 129 M | 106 M | 89.8 M | 78.2 M | - |
Operating Income |
42.8 M | 43 M | 22.8 M | -42.9 M | 123 M | 98.2 M | 107 M | 29.8 M | -13.3 M | 82.9 M | 68.6 M | 39 M | 51.9 M | 61.3 M | 65.2 M | 47.7 M | 35.4 M | 31.4 M | 24.6 M | - |
Interest Expense |
93.3 M | 107 M | 103 M | 70.8 M | 858 K | 1.75 M | 549 K | 709 K | 2.05 M | 118 K | 39 K | - | - | - | - | - | - | - | - | - |
EBITDA |
244 M | 262 M | 252 M | 192 M | 213 M | 184 M | 231 M | 264 M | 137 M | 118 M | 99.9 M | 63.6 M | 71.5 M | 80.3 M | 66.8 M | 65 M | 51.1 M | 45.6 M | 36.4 M | - |
Operating Expenses |
779 M | 782 M | 717 M | 741 M | 368 M | 363 M | 326 M | 381 M | 355 M | 102 M | 98.9 M | 107 M | 103 M | 95.2 M | 93.9 M | 81.3 M | 70.8 M | 58.4 M | 53.6 M | - |
General and Administrative Expenses |
625 M | 639 M | 607 M | 608 M | 303 M | 284 M | 277 M | 328 M | 304 M | 89.4 M | 83.2 M | 88.9 M | 90.4 M | 84.6 M | 85.3 M | 76.6 M | 68.2 M | 53.6 M | 45.5 M | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement ICU Medical
| 2026-Q2 | 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | 2010-Q3 | 2010-Q2 | 2010-Q1 | 2009-Q3 | 2009-Q2 | 2009-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
25 M | 24.8 M | 24.7 M | 24.6 M | 24.5 M | 24.5 M | 24.4 M | 24.4 M | 24.2 M | 24.1 M | 24.1 M | 24.1 M | 24 M | 24 M | 23.9 M | 23.9 M | 23.6 M | 21.3 M | 21.2 M | 21.2 M | 21.1 M | 21.1 M | 20.9 M | 20.9 M | 20.8 M | 20.7 M | 20.7 M | 20.6 M | 20.5 M | 20.5 M | 20.5 M | 20.4 M | 20.3 M | 20.2 M | 20 M | 19.8 M | 18.4 M | 16.3 M | 16.2 M | 16.1 M | 16 M | 16.1 M | 15.9 M | 15.8 M | 15.7 M | 15.6 M | 15.3 M | 15.2 M | 15.1 M | 15.1 M | 14.7 M | 14.6 M | 14.5 M | 14.5 M | 14.3 M | 14.2 M | 14 M | 14.5 M | 13.9 M | 13.9 M | 13.7 M | 13.5 M | 13.5 M | 13.9 M | 14.8 M | 14.8 M | 14.7 M |
Net Income |
19.1 M | 30.1 M | -3.4 M | 35.3 M | -15.5 M | - | -33 M | -21.4 M | -39.5 M | - | 7.24 M | -9.93 M | -9.81 M | - | -13.2 M | -7.47 M | -38.1 M | - | 31.1 M | 28.4 M | 23.7 M | 26.1 M | 25 M | 18.9 M | 18.9 M | 20.6 M | 26.6 M | 22.8 M | 31 M | -7.36 M | 219 K | 31.1 M | 4.88 M | 49.7 M | 136 K | -37.1 M | 55.9 M | 9.51 M | 18.8 M | 16.6 M | 18.2 M | 5.46 M | 16.3 M | 13.6 M | 9.69 M | 7.37 M | 6.43 M | 5.88 M | 6.66 M | 13.3 M | 11 M | 7.37 M | 8.68 M | 12.3 M | 12.2 M | 9.15 M | 7.6 M | 17.8 M | 9.26 M | 9.49 M | 8.07 M | 8.98 M | 7.71 M | 4.26 M | 6.32 M | 5.74 M | 7.06 M |
Revenue |
552 M | 530 M | 537 M | 549 M | 605 M | - | 589 M | 596 M | 567 M | - | 553 M | 549 M | 569 M | - | 598 M | 561 M | 543 M | - | 336 M | 322 M | 318 M | 320 M | 319 M | 303 M | 632 M | 316 M | 307 M | 312 M | 331 M | 340 M | 327 M | 360 M | 372 M | 370 M | 343 M | 332 M | 248 M | 95.7 M | 97.1 M | 96.7 M | 89.9 M | 90.4 M | 86 M | 83.8 M | 81.5 M | 79.9 M | 77.5 M | 78.7 M | 73.2 M | 77.9 M | 82.8 M | 78.7 M | 74.3 M | 82.7 M | 81.4 M | 77.3 M | 75.5 M | 76.5 M | 76.5 M | 77.8 M | 71.5 M | 75.7 M | 68.9 M | 64.4 M | 54 M | 53.4 M | 54.3 M |
Cost of Revenue |
317 M | 324 M | 336 M | 341 M | 395 M | - | 384 M | 389 M | 381 M | - | 369 M | 357 M | 377 M | - | 411 M | 393 M | 374 M | - | 208 M | 198 M | 205 M | - | 205 M | 197 M | 404 M | - | 189 M | 208 M | 196 M | - | 193 M | 209 M | 223 M | - | 232 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
235 M | 206 M | 201 M | 208 M | 210 M | - | 205 M | 207 M | 185 M | - | 184 M | 192 M | 192 M | - | 186 M | 168 M | 169 M | - | 128 M | 124 M | 113 M | 120 M | 114 M | 106 M | 228 M | 114 M | 119 M | 104 M | 135 M | 135 M | 135 M | 152 M | 149 M | 137 M | 112 M | 88.1 M | 88.9 M | 50.8 M | 51.3 M | 50.1 M | 49.2 M | 48.3 M | 46.3 M | 43.8 M | 42.5 M | 39.7 M | 38.1 M | 37.5 M | 36 M | 38.9 M | 41 M | 38 M | 36.8 M | 41.8 M | 40.7 M | 39.1 M | 35 M | 36 M | 35.6 M | 36.2 M | 34.6 M | 34 M | 32.1 M | 26.9 M | 25 M | 25.8 M | 26.6 M |
Operating Income |
39.1 M | 13.6 M | 13.7 M | 10.6 M | 12.9 M | - | 8.24 M | 7.69 M | -10.7 M | - | 22.9 M | 2.76 M | 9.4 M | - | -467 K | -48 K | -42.2 M | - | 38.4 M | 34.5 M | 26.6 M | - | 25.5 M | 19.6 M | 45.6 M | - | 32.9 M | 26.3 M | 30.4 M | - | 2.25 M | 31.7 M | 4.91 M | - | -3.7 M | -35.9 M | -17 M | - | 22.5 M | 22.8 M | 23.9 M | - | 24.8 M | 20.3 M | 11 M | - | 8.41 M | 8.7 M | 9.88 M | - | 15.4 M | 11 M | 12 M | - | 17.5 M | 13.5 M | 11.4 M | - | 13.3 M | 14 M | 12.2 M | 14.6 M | 11.8 M | 6.35 M | 7.64 M | 8.67 M | 10.7 M |
Interest Expense |
15.7 M | 16.5 M | 19.8 M | 20.5 M | 22 M | - | 24.7 M | 23.8 M | 23.8 M | - | 24.2 M | 24.1 M | 22.5 M | - | 17.8 M | 15.4 M | 13.6 M | - | 168 K | 163 K | 161 K | - | 616 K | 771 K | 967 K | - | 139 K | 139 K | 133 K | - | 283 K | 130 K | 135 K | - | 705 K | 525 K | 513 K | - | 58 K | 48 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
139 M | 63.6 M | 31.4 M | 27.5 M | 62.3 M | - | 29.6 M | 30 M | 44.9 M | - | 47.9 M | 27.2 M | 65.1 M | - | 22.5 M | 24.9 M | 11 M | - | 105 M | 78.8 M | 48.7 M | - | 89.6 M | 35.4 M | 88.2 M | - | 89.9 M | 64.1 M | 49.4 M | - | 57.3 M | 67.6 M | 23.2 M | - | 43.8 M | -6.03 M | -5.39 M | - | 36.8 M | 32.4 M | 28.7 M | - | 38 M | 29.3 M | 15.6 M | - | 23.1 M | 18.4 M | 14.6 M | - | 29.9 M | 20.5 M | 16.7 M | - | 31.8 M | 23.1 M | 16.2 M | - | 27 M | 23 M | 16.7 M | 27.4 M | 20.4 M | 10.9 M | 18.9 M | 16 M | 14.3 M |
Operating Expenses |
196 M | 193 M | 187 M | 197 M | 197 M | - | 197 M | 200 M | 196 M | - | 161 M | 190 M | 183 M | - | 187 M | 168 M | 211 M | - | 89.4 M | 89.1 M | 86.1 M | - | 88.4 M | 86.7 M | 182 M | - | 85.7 M | 77.6 M | 105 M | - | 132 M | 120 M | 144 M | - | 115 M | 124 M | 106 M | - | 28.8 M | 27.4 M | 25.3 M | - | 21.5 M | 23.4 M | 31.5 M | - | 29.7 M | 28.8 M | 26.2 M | - | 25.5 M | 27.1 M | 24.8 M | - | 23.2 M | 25.5 M | 23.6 M | - | 22.3 M | 22.2 M | 22.4 M | 19.4 M | 20.3 M | 20.6 M | 17.4 M | 17.1 M | 15.8 M |
General and Administrative Expenses |
152 M | 155 M | 153 M | 159 M | 157 M | - | 163 M | 160 M | 158 M | - | 149 M | 151 M | 153 M | - | 153 M | 159 M | 153 M | - | 74.8 M | 73.9 M | 72.4 M | - | 70.9 M | 67.2 M | 140 M | - | 65.9 M | 67.8 M | 72.6 M | - | 76.6 M | 81.8 M | 85 M | - | 76.8 M | 85.1 M | 64.9 M | - | 22.4 M | 22.5 M | 22 M | - | 20.2 M | 20.3 M | 20.2 M | - | 21.8 M | 24.3 M | 22.5 M | - | 22.4 M | 23.2 M | 22.9 M | - | 20.2 M | 22.8 M | 20.9 M | - | 20.4 M | 19.7 M | 22.9 M | 18.3 M | 19.4 M | 19.7 M | 16.8 M | 16.5 M | 15.1 M |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company ICU Medical (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
ResMed
RMD
|
$ 246.2 | 0.31 % | $ 35.8 B |  USA |
 |
OraSure Technologies
OSUR
|
$ 3.86 | 3.07 % | $ 284 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 9.08 | 2.37 % | $ 1.81 B | USA |
 |
Teleflex Incorporated
TFX
|
$ 130.4 | -0.57 % | $ 5.82 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
The Cooper Companies
COO
|
$ 58.97 | -0.25 % | $ 11.7 B | USA |
 |
Microbot Medical
MBOT
|
$ 0.94 | -0.78 % | $ 43 M |  Israel |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Masimo Corporation
MASI
|
- | - | $ 9.59 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
BioLife Solutions
BLFS
|
$ 38.61 | 3.51 % | $ 1.84 B | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 194.34 | 0.3 % | $ 55.9 B | USA |
 |
Alcon
ALC
|
$ 67.43 | -0.58 % | $ 33.3 B |  Schweiz |
 |
Intuitive Surgical
ISRG
|
$ 428.12 | -2.26 % | $ 153 B | USA |
 |
Repro Med Systems
KRMD
|
$ 3.11 | 2.3 % | $ 144 M | USA |
 |
AtriCure
ATRC
|
$ 57.67 | -0.23 % | $ 2.75 B | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Milestone Scientific
MLSS
|
$ 0.31 | -8.31 % | $ 25.4 M | USA |
 |
Merit Medical Systems
MMSI
|
$ 91.4 | 0.24 % | $ 5.41 B | USA |
 |
Nephros
NEPH
|
$ 3.59 | 1.99 % | $ 38.1 M | USA |
 |
electroCore
ECOR
|
$ 7.35 | -1.87 % | $ 62.4 K | USA |
 |
Envista Holdings Corporation
NVST
|
$ 23.19 | 0.96 % | $ 3.9 B | USA |
 |
Baxter International
BAX
|
$ 24.7 | 0.78 % | $ 12.7 B | USA |
 |
Pro-Dex
PDEX
|
$ 60.56 | 1.96 % | $ 195 B | USA |
 |
Pulse Biosciences
PLSE
|
$ 51.31 | 0.92 % | $ 3.46 B | USA |
 |
Repligen Corporation
RGEN
|
$ 180.01 | 0.63 % | $ 10.1 M | USA |
 |
Retractable Technologies
RVP
|
$ 0.58 | -0.02 % | $ 17.4 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 21.61 | -3.18 % | $ 1.07 B | USA |
 |
STERIS plc
STE
|
$ 221.48 | -1.58 % | $ 21.7 B | USA |
 |
Stereotaxis
STXS
|
$ 0.99 | -0.34 % | $ 90 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 14.05 | -1.26 % | $ 290 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 176.85 | 1.97 % | $ 10.1 B | USA |
 |
Utah Medical Products
UTMD
|
$ 74.72 | -0.47 % | $ 242 M | USA |
 |
AngioDynamics
ANGO
|
$ 11.89 | 0.68 % | $ 494 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 117.11 | -0.93 % | $ 5.53 B | USA |
 |
West Pharmaceutical Services
WST
|
$ 393.48 | 1.21 % | $ 28.4 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 113.55 | -0.26 % | $ 3.63 B | USA |
 |
LeMaitre Vascular
LMAT
|
$ 83.67 | 0.32 % | $ 1.89 B | USA |
 |
Harvard Bioscience
HBIO
|
$ 8.49 | 1.8 % | $ 377 M | USA |